Datamonitor, Dec 2010, Pages: 53
Introduction
The analysis examines the historical and forecast performance for Mylan in the generic prescription pharmaceutical sector. The profile encompasses global company strategy
Datamonitor, Nov 2010, Pages: 76
questions answered
- Benchmark Servier's performance against key rivals in the prescription pharmaceutical sector
- Asses how Servier will perform in the face of growing generic competition facing its number
Datamonitor, Oct 2010, Pages: 19
in the prescription pharmaceutical sector.
- Assess how Sandoz will sustain its pioneering position in the biosimilars market via the launch of generic Lovenox (enoxaparin) in 2010.
- Analyse how challenging US
Datamonitor, Dec 2010, Pages: 62
enhanced geographic footprint
- Assess how Watson will compete in an increasingly competitive generics market with enhanced specialist players and an increased Big Pharma presence
Executive Summary
Key
Datamonitor, Dec 2010, Pages: 128
Introduction
Historical and forecast analysis of the PharmaVitae Universe from 2003 through to 2015. Strategic dynamics within the Universe are segmented by peer set, therapy area, launch/core
Datamonitor, Nov 2011, Pages: 103
THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Datamonitor, Nov 2010, Pages: 135
with an enhanced focus on the vaccine, generic and consumer markets.
- Assess how the genericization of blockbusters Plavix, Eloxatine, Taxotere, Stilnox/Ambien and Lovenox is expected to significantly impact growth
Datamonitor, Nov 2010, Pages: 83
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–
Operating costs and profit analysis
King Pharmaceuticals: PharmaVitae forecasts at a glance
Datamonitor, Dec 2010, Pages: 79
: PharmaVitae forecasts at a glance
Strategic insight
Baxter’s hold of the hemophilia market
‘Wild card’ Gammagard (CNS) essential for growth
SWOT analysis
ABOUT THIS PROFILE
PharmaVitae
Datamonitor, Dec 2010, Pages: 67
, will generate new growth for the company
Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–
Operating costs and profit analysis
COMPANY: PharmaVitae
Datamonitor, Dec 2010, Pages: 73
: PharmaVitae forecasts at a glance
Strategic insight
[Missing title]
New launches struggle to match the decline of existing products
External product deals needed to extend growth
Datamonitor, Dec 2010, Pages: 88
performance, 2003–
Cephalon: PharmaVitae forecasts at a glance
Strategic insight
Generic sales erosion of key products only slightly offset by product lifecycle management strategies
More
Datamonitor, Dec 2010, Pages: 37
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company
Datamonitor, Dec 2010, Pages: 124
strategies across its portfolio as a means to combat patent expiries and generic competition
- Assess J&J's diverse healthcare offering and how this will act to maintain operating profit growth despite
Datamonitor, May 2011, Pages: 90
and emerging markets positioned as key growth opportunities.
- Analyse how life-cycle managment (and a lack of generic competition) will facilitate GSK's continued strong position in the global asthma/COPD
Datamonitor, Oct 2011, Pages: 128
generic entry.
Your key questions answered
- Assess the outlook for the monoclonal antibodies sector through to 2016
- Evaluate the impact of monoclonal antibody on company performances across the PharmaVitae
